LLY:NYE-Eli Lilly and Company (USD)

COMMON STOCK | Drug Manufacturers-General | NYE

Last Closing Price

USD 255.99

Change

+9.39 (+3.81)%

Market Cap

USD 233.52B

Volume

5.35M

Avg Analyst Target

USD 241.85 (-5.53%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; MiNA Therapeutics Limited; Verge Genomics; and The Banner Alzheimer's Institute. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ Johnson & Johnson

+2.12 (+1.23%)

USD453.47B 25.89 24.23
PFE Pfizer Inc

+1.72 (+3.91%)

USD239.64B 18.28 15.78
NVS Novartis AG

+0.44 (+0.48%)

USD207.12B 23.41 13.03
ABBV AbbVie Inc

+0.80 (+0.69%)

USD205.41B 31.36 18.98
MRK Merck & Co., Inc

+0.23 (+0.30%)

USD194.64B 35.00 31.50
BMY Bristol-Myers Squibb Company

+1.29 (+1.90%)

USD151.15B 213.75 22.97
GSK GlaxoSmithKline plc

+0.40 (+0.99%)

USD100.99B 16.55 12.14
AGN Allergan plc

N/A

USD63.66B 22.00 28.44

ETFs Containing LLY

Symbol Name Weight Mer Price(Change) Market Cap
CATH Global X S&P 500 Catholic.. 0.00 % 0.29 %

+0.38 (+0.70%)

USD0.56B
XSHC:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

-3.80 (-0.10%)

USD0.59B
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.72 %

N/A

USD0.08B
PQLC PGIM QMA Strategic Alpha .. 0.00 % 0.17 %

+0.58 (+0.79%)

USD0.01B
LS:CA Middlefield Healthcare & .. 0.00 % 1.31 %

+0.24 (+2.08%)

USD0.09B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

N/A
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.74 %

+0.26 (+2.21%)

N/A
BUYB:LSE Invesco Markets III plc -.. 0.00 % 0.39 %

-0.02 (-0.04%)

USD0.07B
IUHC:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+0.01 (+0.10%)

USD1.80B
SXLV:LSE SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

+0.09 (+0.24%)

USD0.25B
VMOM:LSE Vanguard Global Momentum .. 0.00 % 0.00 %

N/A

USD0.07B
XDWE:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

-23.50 (-0.41%)

USD5.80B
XUHC:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

-0.02 (-0.03%)

USD0.59B
JMIN JPMorgan U.S. Minimum Vol.. 0.00 % 0.12 %

+0.23 (+0.63%)

USD0.02B
XMVU:LSE Xtrackers (IE) Plc - Xtra.. 0.00 % 0.20 %

N/A

USD5.54M
FLXU:F Franklin LibertyShares IC.. 0.00 % 0.25 %

+0.11 (+0.29%)

USD0.09B
MJMT:F Amundi Index Solutions - .. 0.00 % 0.00 %

+0.71 (+0.79%)

USD0.39B
QDVG:F iShares V Public Limited .. 0.00 % 0.15 %

+0.06 (+0.65%)

USD1.79B
XDWH:F Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

+0.24 (+0.57%)

USD1.10B
ZPDH:F SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

+0.21 (+0.63%)

USD0.25B
FLXU:XETRA Franklin LibertyShares IC.. 0.00 % 0.25 %

+0.03 (+0.07%)

USD0.11B
MJMT:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

+0.52 (+0.58%)

USD0.46B
QDVG:XETRA iShares V Public Limited .. 0.00 % 0.15 %

+0.03 (+0.39%)

USD1.80B
VMUS:XETRA VanEck Vectors ETFs N.V. .. 0.00 % 0.00 %

-0.12 (-0.26%)

USD9.68M
XUHC:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

+0.17 (+0.37%)

USD0.59B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

+0.16 (+0.62%)

USD0.02B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.45 %

+0.21 (+0.90%)

USD0.01B
CURE Direxion Shares ETF Trust.. 0.00 % 1.01 %

+5.02 (+4.16%)

USD0.17B
PPH VanEck Vectors ETF Trust .. 0.00 % 0.35 %

+0.52 (+0.69%)

USD0.23B
FHLC Fidelity MSCI Health Care.. 0.00 % 0.08 %

+0.74 (+1.12%)

USD2.70B
FVD First Trust Value Line Di.. 0.00 % 0.70 %

+0.30 (+0.74%)

USD11.81B
FVL First Trust Value Line 10.. 0.00 % 0.70 %

N/A

USD0.04B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+3.11 (+1.61%)

USD0.38B
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

+1.09 (+1.26%)

USD3.10B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

+4.07 (+1.42%)

USD2.66B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

+0.53 (+1.07%)

USD0.05B
KRMA Global X Conscious Compan.. 0.00 % 0.43 %

+0.14 (+0.43%)

USD0.47B
PILL Direxion Daily Pharmaceut.. 0.00 % 1.00 %

+0.52 (+2.33%)

USD0.02B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

+0.69 (+0.85%)

USD0.37B
QDEF FlexShares Quality Divide.. 0.00 % 0.37 %

+0.47 (+0.86%)

USD0.48B
FLUS:CA Franklin LibertyQT U.S. E.. 0.00 % 0.28 %

+0.21 (+0.66%)

USD0.11B
RFDA RiverFront Dynamic US Div.. 0.00 % 0.52 %

+0.30 (+0.68%)

USD0.13B
RFFC RiverFront Dynamic US Fle.. 0.00 % 0.52 %

+0.35 (+0.78%)

USD0.06B
ROUS Hartford Multifactor US E.. 0.00 % 0.19 %

+0.30 (+0.73%)

USD0.39B
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

+2.57 (+2.52%)

USD0.22B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

+3.08 (+1.20%)

USD17.94B
XLV Health Care Select Sector.. 0.00 % 0.12 %

+1.84 (+1.39%)

USD27.88B
XMS:CA iShares MSCI Min Vol USA .. 0.00 % 0.33 %

-0.03 (-0.09%)

USD0.05B
XMU:CA iShares MSCI Min Vol USA .. 0.00 % 0.33 %

+0.54 (+0.84%)

USD0.31B
XPH SPDR Series Trust - SPDR .. 0.00 % 0.35 %

+0.46 (+0.90%)

USD0.27B
HHL:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

+0.08 (+0.93%)

USD0.33B
DFU:CA Desjardins USA Multifacto.. 0.00 % 0.58 %

N/A

USD4.22M
ZPDH:XETRA SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

+0.14 (+0.41%)

USD0.25B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 51.62% 100% A+ 92% A-
Dividend Return 1.01% 13% F 36% F
Total Return 52.62% 100% A+ 92% A-
Trailing 12 Months  
Capital Gain 65.31% 100% A+ 81% B-
Dividend Return 2.05% 13% F 35% F
Total Return 67.37% 100% A+ 81% B-
Trailing 5 Years  
Capital Gain 210.59% 100% A+ 93% A
Dividend Return 14.64% 38% F 52% F
Total Return 225.24% 100% A+ 93% A
Average Annual (5 Year Horizon)  
Capital Gain 23.85% 100% A+ 86% B
Dividend Return 2.33% 25% F 56% F
Total Return 26.18% 100% A+ 86% B
Risk Return Profile  
Volatility (Standard Deviation) 18.27% 25% F 59% F
Risk Adjusted Return 143.32% 100% A+ 98% A+
Market Capitalization 233.52B 75% C 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.45 25% F 20% F
Price/Book Ratio 33.85 13% F 2% F
Price / Cash Flow Ratio 35.93 13% F 10% F
EV/EBITDA 28.09 25% F 19% F
Management Effectiveness  
Return on Equity 118.34% 88% B+ 97% A+
Return on Invested Capital 28.95% 100% A+ 95% A
Return on Assets 10.08% 88% B+ 93% A
Debt to Equity Ratio 294.01% 25% F 10% F
Technical Ratios  
Short Ratio 2.17 75% C 49% F
Short Percent 0.82% 63% D 81% B-
Beta 0.26 100% A+ 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector